Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03649880 · ClinicalTrials.gov registry record · Phase 2
Feasibility of FMISO in Brain Tumors
A Phase 2 study of Malignant Brain Neoplasm, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03649880 is a Phase 2 study of Malignant Brain Neoplasm that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 50 participants, below the 225-participant average among 12 other Malignant Brain Neoplasm trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03649880, a Phase 2 study of Malignant Brain Neoplasm, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG ¹⁸F-Fluoromisonidazole
- PROCEDURE Oxygen Therapy
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03649880
The ClinicalTrials.gov registry entry for NCT03649880 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 12 other Malignant Brain Neoplasm trials with a reported enrollment target (78% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Brain Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT03649880 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03649880 about?
NCT03649880 is a clinical study titled "Feasibility of FMISO in Brain Tumors". This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how t...
What is the current status of trial NCT03649880?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2019-06-01. Estimated completion is 2030-01-31.
What conditions does trial NCT03649880 study?
This clinical trial studies the following conditions: Malignant Brain Neoplasm.
What interventions are being tested in trial NCT03649880?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), ¹⁸F-Fluoromisonidazole (DRUG), Oxygen Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT03649880?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03649880 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
RECRUITING · NA
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.